Skip to main content

Table 3 Most common TEAEs (reported at any grade in ≥ 2 patients) for maintenance and treatment

From: Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

 

ALL GRADES

GRADE 3

Maintenance ( n = 18)

Nausea

7 (39%)

1 (6%)

ALT/AST increase

5 (28%)

1 (6%)

Fatigue

5 (28%)

0

Diarrhoea

4 (22%)

0

Creatinine increased

4 (22%)

0

ALP increase

2 (11%)

1 (6%)

Anaemia

2 (11%)

2 (11%)

Neutropenia

2 (11%)

0

Dysgeusia

2 (11%)

0

Vomiting

2 (11%)

0

Abdominal pain

2 (11%)

0

Anorexia

2 (11%)

0

Treatment (n=33)

Anaemia

13 (39%)

5 (15%)

Thrombocytopenia

10 (30%)

2 (6%)

Fatigue

7 (21%)

2 (6%)

Nausea

5 (15%)

0

ALT/AST increase

4 (12%)

0

Neutropenia

3 (9%)

2 (6%)

Vomiting

3 (9%)

2 (6%)

ALP increase

3 (9%)

1 (3%)

Asthenia

3 (9%)

0

Abdominal pain

2 (6%)

1 (3%)

Hyporexia

2 (6%)

0

Constipation

2 (6%)

0

  1. Data are n (%). TEAEs were graded according to Common Terminology Criteria for Adverse Events version 5.0, with the highest grade reported if patients reported the same event at more than one grade. ALP: alkaline phosphatase. ALT: alanine aminotransferase. AST: aspartate aminotransferase. TEAE: treatment-emergent adverse event.